Opioid receptor binding characteristics and structure-activity studies of novel tetrapeptides in the TIPP (Tyr-Tic-Phe-Phe) series

NeuroSignals

Volumn 14, Issue 6, 2006, Pages 317-328

  Ioja, Eniko ^a   Tóth, Géza ^a   Benyhe, Sándor ^a   Tourwe, Dirk ^c   Péter, Antal ^b   Tömböly, Csaba ^c   Borsodi, Anna ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

35S GTP S binding; Chinese hamster ovary (CHO) cell lines; Delta antagonist peptides; Opioid receptors; Radioligand binding; Rat brain, opioid receptors

Indexed keywords

AMIDE; AMINO ACID; DELTA OPIATE RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MU OPIATE RECEPTOR; OPIATE ANTAGONIST; OPIATE RECEPTOR; PEPTIDE DERIVATIVE; TETRAPEPTIDE; TYROSINE;

AMIDATION; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CARBOXY TERMINAL SEQUENCE; CHO CELL; CONTROLLED STUDY; DRUG DEPENDENCE; NONHUMAN; RADIORECEPTOR ASSAY; RAT; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANALGESICS, OPIOID; ANIMALS; CELL MEMBRANE; CELLS, CULTURED; CHO CELLS; CRICETINAE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); MOLECULAR CONFORMATION; OLIGOPEPTIDES; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; RECEPTORS, OPIOID; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAHYDROISOQUINOLINES;

EID: 33745033972     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093046     Document Type: Article

References (38)

1. Massotte D, Kieffer BL: A molecular basis for opiate action. Essays Biochem 1998;33:65-77.
2. Narita M, Funada M, Suzuki T: Regulations of opioid dependence by opioid receptor types. Pharmacol Ther 2001;89:1-15.
3. Coop A, Rice KC: Role of delta-opioid receptors in biological processes. Drug News Perspect 2000;13:481-487.
4. Arakawa K, Akami T, Okamoto M, Nakajima H, Mitsuo M, Nakai I, Oka T, Nagase H, Matsumoto S: Immunosuppressive effect of delta-opioid receptor antagonist on xenogeneic mixed lymphocyte reaction. Transplant Proc 1992;24:696-697.
5. Krishnan-Sarin S, Jing SL, Kurtz DL, Zweifel M, Portoghese PS, Li TK, Froehlich JC: The delta opioid receptor antagonist naltrindole attenuates both alcohol and saccharin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl) 1995;120:177-185.
6. Reid LD, Glick SD, Menkens KA, French ED, Bilsky EJ, Porreca F: Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. Neuroreport 1995;6:1409-1412.
7. Takemori AE, Portoghese PS: Selective naltrexone-derived opioid receptor antagonists. Annu Rev Pharmacol Toxicol 1992;32:239-269.
8. Schutz J, Dersch CM, Horel R, Spetea M, Koch M, Meditz R, Greiner E, Rothman RB, Schmidhammer H: Synthesis and biological evaluation of 14-alkoxymorphinans. 17. Highly delta opioid receptor selective 14-alkoxy-substituted indolo- and benzofuromorphinans. J Med Chem 2002;45:5378-5383.
9. Schiller PW, Weltrowska G, Berezowska I, Nguyen TM, Wilkes BC, Lemieux C, Chung NN: The TIPP opioid peptide family: development of delta antagonists, delta agonists, and mixed mu agonist/delta antagonists. Biopolymers 1999;51:411-425.
10. Schiller PW, Nguyen TM, Weltrowska G, Wilkes BC, Marsden BJ, Lemieux C, Chung NN: Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. Proc Natl Acad Sci USA 1992;89:11871-11875.
11. Schiller PW, Weltrowska G, Nguyen TM, Wilkes BC, Chung NN, Lemieux C: TIPP[ψ]: a highly potent and stable pseudopeptide delta opioid receptor antagonist with extraordinary delta selectivity. J Med Chem 1993;36:3182-3187.
12. 3H]TIPP. Life Sci 1993;53:PL57-PL62.
13. Nevin ST, Tóth G, Weltrowska G, Schiller PW, Borsodi A: Synthesis and binding characteristics of tritiated TIPP[ψ], a highly specific and stable delta opioid antagonist. Life Sci 1995;56:PL225-PL230.
14. Schiller PW, Nguyen TM, Weltrowska G, Wilkes BC, Marsden BJ, Schmidt R, Lemieux C, Chung NN: TIPP opioid peptides: development of extraordinarily potent and selective δantagonists and observation of astonishing structure-intrinsic activity relationships; in Hodges RS, Smith JA (eds): Peptides - Chemistry, Structure and Biology: Proceedings of the 13th American Peptide Symposium. Leiden, ESCOM Science Publishers, 1994, pp 483-486.
15. Schiller PW, Weltrowska G, Nguyen TM, Lemieux C, Chung NN, Zelent B, Wilkes BC, Carpenter KA: Structure-agonist/antagonist activity relationships of TIPP analogs; in Kumaya PT, Hodges RS (eds): Peptides - Chemistry, Structure and Biology: Proceedings of the 14th American Peptide Symposium. Kingswinford, Mayflower Scientific, 1996, pp 609-611.
16. Salvadori S, Attila M, Balboni G, Bianchi C, Bryant SD, Crescenzi O, Guerrini R, Picone D, Tancredi T, Temussi PA, et al: Delta opioidmimetic antagonists: prototypes for designing a new generation of ultraselective opioid peptides. Mol Med 1995;1:678-689.
17. Bryant SD, Salvadori S, Cooper PS, Lazarus LH: New δ-opioid antagonists as pharmacological probes. Trends Pharmacol Sci 1998;19:41-46.
18. Schiller PW, Weltrowska G, Schmidt R, Berezowska I, Nguyen TM, Lemieux C, Chung NN, Carpenter KA, Wilkes BC: Subtleties of structure-agonist versus antagonist relationships of opioid peptides and peptidomimetics. J Recept Signal Transduct Res 1999;19:573-588.
19. Hruby VJ, al-Obeidi F, Kazmierski W: Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. Biochem J 1990;268:249-262.
20. 5]enkephalin. J Med Chem 1991;34:1823-1830.
21. 2 analog with balanced mixed μ-agonist/δ-antagonist properties. Regul Pept 1994;54:257-258.
22. Tourwé D, Mannekens E, Diem TN, Verheyden P, Jaspers H, Tóth G, Péter A, Kertész I, Török G, Chung NN, Schiller PW: Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile. J Med Chem 1998;41:5167-5176.
23. 5,6 deltorphin-II. Neuropeptides 1994;26:261-265.
24. Tourwé D, Tóth G, Carlens G, Tömböly C, Péter A, Schiller PW: Beta methyl substitution of the Cha residue in Dmt-Tic-Cha-Phe peptides provides highly potent delta antagonists; in Chorev M, Sawyer TK (eds): Peptide Revolution: Genomics, Proteomics and Therapeutics: Proceedings of 18th American Peptide Symposium 2003, pp 582-583.
25. 7, an endogenous neropeptide, binds to multiple opioid and non-opioid sites in rat brain. J Neurosci Res 1997;48:249-258.
26. Stannard P, Platt M, Pilkington J: GraphPad Prism 2.01. San Diego, GraphPad Software, 1995, pp 1-373.
27. Spetea M, Monory K, Tömböly C, Tóth G, Tzavara E, Benyhe S, Hanoune J, Borsodi A: In vitro binding and signaling profile of the novel μ-opioid receptor agonist endomorphin-2 in rat brain membranes. Biochem Biophys Res Commun 1998;250:720-725.
28. 35S]GTPγS binding assay: approaches and applications in pharmacology. Life Sci 2003;74:489-508.
29. Clark MJ, Emmerson PJ, Mansour A, Akil H, Woods JH, Portoghese PS, Remmers AE, Medzihradsky F: Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J Pharmacol Exp Ther 1997;283:501-510.
30. 35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects. J Pharmacol Exp Ther 1997;283:1276-1284.
31. 5-enkephalin to brain regions and spinal cord and pharmacological responses to morphine in the rat. Gen Pharmacol 1993;24:1351-1357.
32. Martin TJ, Dworkin SI, Smith JE: Alkylation of mu opioid receptors by beta-funaltrexamine in vivo: comparison of the effects on in situ binding and heroin self-administration in rats. J Pharmacol Exp Ther 1995;272:1135-1140.
33. Ko MC, Lee H, Harrison C, Clark MJ, Song HF, Naughton NN, Woods JH, Traynor JR: Studies of micro-, kappa-, and delta-opioid receptor density and G protein activation in the cortex and thalamus of monkeys. J Pharmacol Exp Ther 2003;306:179-186.
34. Martin NA, Ruckle MB, VanHoof SL, Prather PL: Agonist, antagonist, and inverse agonist characteristics of TIPP (H-Tyr-Tic-Phe-Phe-OH), a selective δ-opioid receptor ligand. J Pharmacol Exp Ther 2002;301:661-671.
35. Martin NA, Terruso MT, Prather PL: Agonist activity of the δ-antagonists TIPP and TIPP-ψ in cellular models expressing endogenous or transfected δ-opioid receptors. J Pharmacol Exp Ther 2001;298:240-248.
36. Amodeo P, Balboni G, Crescenzi O, Guerrini R, Picone D, Salvadori S, Tancredi T, Temussi PA: Conformational analysis of potent and very selective delta opioid dipeptide antagonists. FEBS Lett 1995;377:363-367.
37. Temussi PA, Salvadori S, Amodeo P, Bianchi C, Guerrini R, Tomatis R, Lazarus LH, Picone D, Tancredi T: Selective opioid dipeptides. Biochem Biophys Res Commun 1994;198:933-939.
38. Hruby VJ, Li G, Haskell-Luevano C, Shenderovich M: Design of peptides, proteins, and peptidomimetics in chi space. Biopolymers 1997;43:219-266.